Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 7 W ELECTROLYTES versus TRAVASOL 8 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN II 7% W/ ELECTROLYTES vs TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is a parenteral nutrition solution that provides a source of amino acids, electrolytes, and calories. The amino acids serve as substrates for protein synthesis and energy metabolism, replenishing nitrogen balance and supporting tissue repair and growth.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
Intravenous infusion. Individualized based on protein and electrolyte requirements. Typical adult dose: 500-2000 mL/day of 8.5% amino acid solution, infused at 60-125 mL/hour.
None Documented
None Documented
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Amino acids have short half-lives (minutes to hours) due to rapid metabolism; no single terminal half-life for mixture. Electrolytes have distribution half-lives of minutes.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Renal: Amino acids are extensively reabsorbed; excess nitrogen is excreted as urea (renal, majority). Electrolytes are excreted renally with reabsorption regulation. Biliary/fecal: Negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution